<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733380</url>
  </required_header>
  <id_info>
    <org_study_id>HNSZLYYML-01</org_study_id>
    <nct_id>NCT02733380</nct_id>
  </id_info>
  <brief_title>Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>The Efficacy and Safety of Chidamide Combined With VDDT Regimen（Vinorelbine，Liposomal Doxorubicin，Dexamethasone and Thalidomide） in Relapse and Refractory Patients With Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide
      combined with VDDT(vinorelbine，liposomal doxorubicin，dexamethasone and thalidomide) in
      relapsed and refractory patients with diffuse large B-cell lymphoma(DLBCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are one third of diffuse large B-cell Lymphoma patients suffering relapse and
      refractory, which are the major cause of death among these patients. Vinorelbine，liposomal
      doxorubicin，mitoxantrone, dexamethasone and thalidomide have been used in the therapy of
      patients who failed with Second-line treatments in our center. This regimen is well tolerated
      but the effect needs to be improved. Chidamide，a histone deacetylase inhibitor has been
      approved for the treatment of refractory T-cell lymphoma in China. The goal is to assess the
      efficacy and safety of chidamide combined with VDDT（vinorelbine，liposomal
      doxorubicin，dexamethasone and thalidomide） in relapse and refractory patients with diffuse
      large B-cell Lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>every 8 weeks until 1 year after last patient's enrollment</time_frame>
    <description>the total proportion of patients with complete response（CR or CRu）and partial response（PR）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>from the date of first cycle of treatment to 1 year after last patient's enrollment</time_frame>
    <description>any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>abnormal laboratory examinations</measure>
    <time_frame>from the date of first enrollment to 1 year after last patient's enrollment</time_frame>
    <description>includes type, incidence, relationship with treatment and severity of abnormal laboratory examinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>incidence and relationship with study drugs of grade 3-4 adverse events and abnormal laboratory examinations</measure>
    <time_frame>from the date of first cycle of treatment to 1 year after last patient's enrollment</time_frame>
    <description>the incidence and relationship with study drugs of grade 3 or 4 adverse events (based on NCI CTC-AE v4.03) and abnormal laboratory examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>from the day of treatment to the date of first documented progression，up to 1 year after last patient's enrollment</time_frame>
    <description>from date of first day of treatment to the date of first documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>from the day of first documented response to first documented progression or death，up to 1 year after last patient's enrollment</time_frame>
    <description>from the first day of documented response to disease progression or death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Chidamide combined with VDDT regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide 30mg，Oral twice a week with an interval of no less than 3 days combined with regimen：VDDT（Vinorelbine，Liposomal doxorubicin or mitoxantrone ，Dexamethasone and Thalidomide）：repeated every 14 days ，up to 12 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops</description>
    <arm_group_label>Chidamide combined with VDDT regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles</description>
    <arm_group_label>Chidamide combined with VDDT regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin or mitoxantrone</intervention_name>
    <description>20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles</description>
    <arm_group_label>Chidamide combined with VDDT regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles</description>
    <arm_group_label>Chidamide combined with VDDT regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks</description>
    <arm_group_label>Chidamide combined with VDDT regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed as diffuse large B-cell Lymphoma based on the 2008 WHO classification of
             tumors of haematopoietic and lymphoid tissues

          2. Failed with second-line therapy

          3. Having at least one measurable lesions

          4. Age between 18 to 75 years old

          5. World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG)
             0-1

          6. Neutrophils more than 1.5*10^9/L; Platelets more than 90*10^9/L Hemoglobin: more than
             90g/L.

          7. Life expectancy no less than 3 months

          8. No receiving chemotherapy in 4 weeks before enrollment

          9. Agreeing to sign the written informed consents

        Exclusion Criteria:

          1. Pregnant ，lactating and patients at reproductive age who refuse to practice
             contraception

          2. QTc prolonging ＞450ms，ventricular tachycardia，atrial fibrillation，cardiac conduction
             block， myocardial infarction in less than 1 year， congestive heart failure，coronary
             heart disease which needs medication.

          3. Organ transplant recipients

          4. Active bleeding

          5. Thrombus，embolism，cerebral hemorrhage，cerebral infarction

          6. Important organ operation in less than 6 weeks

          7. Abnormal liver function（Note：total bilirubin ＞1.5 times the upper limit of normal，AST
             or ALT ＞2.5 times the upper limit of normal （Note：5 times the upper limit of normal
             for patients with liver involvement）），abnormal renal function（Note：serum creatinine
             ＞1.5 times the upper limit of normal），fluid and electrolyte disorders

          8. Mental illness or unable to sign the informed consent

          9. Drug addiction history or alcoholism which may interfere the experimental results.

         10. Researchers determine unsuited to participate in this trial

         11. Known allergy to any kind of study drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanyan Liu, M.D. Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanyan Liu, M.D. Ph.D</last_name>
    <phone>+8613818176375</phone>
    <email>yyliu@zzu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiuyang Zhang, Master</last_name>
    <phone>+8615003810435</phone>
    <email>zhangjiuyang9103@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanyan Liu, M.D.</last_name>
      <phone>+8613838176375</phone>
      <email>yyliu@zzu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jiuyang Zhang, Master</last_name>
      <phone>+8615003810435</phone>
      <email>zhangjiuyang9103@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yanyan Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wynder EL. Listen to nature. The challenge of lifestyle medicine. Soz Praventivmed. 1991;36(3):137-46. Review.</citation>
    <PMID>1950172</PMID>
  </results_reference>
  <results_reference>
    <citation>Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009 May 8;277(1):8-21. doi: 10.1016/j.canlet.2008.08.016. Epub 2008 Sep 27. Review.</citation>
    <PMID>18824292</PMID>
  </results_reference>
  <results_reference>
    <citation>Khan AN, Tomasi TB. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res. 2008;40(2):164-78. doi: 10.1007/s12026-007-0085-0. Review.</citation>
    <PMID>18213528</PMID>
  </results_reference>
  <results_reference>
    <citation>Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, Kasper LH, Lerach S, Tang H, Ma J, Rossi D, Chadburn A, Murty VV, Mullighan CG, Gaidano G, Rabadan R, Brindle PK, Dalla-Favera R. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011 Mar 10;471(7337):189-95. doi: 10.1038/nature09730.</citation>
    <PMID>21390126</PMID>
  </results_reference>
  <results_reference>
    <citation>Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298-303. doi: 10.1038/nature10351.</citation>
    <PMID>21796119</PMID>
  </results_reference>
  <results_reference>
    <citation>Mondello P, Younes A. Emerging drugs for diffuse large B-cell lymphoma. Expert Rev Anticancer Ther. 2015 Apr;15(4):439-51. doi: 10.1586/14737140.2015.1009042. Epub 2015 Feb 5. Review.</citation>
    <PMID>25652253</PMID>
  </results_reference>
  <results_reference>
    <citation>Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF, Meng ZY, Shi YK, Lu XP, Feng FY. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012 Jun;69(6):1413-22. doi: 10.1007/s00280-012-1847-5. Epub 2012 Feb 24.</citation>
    <PMID>22362161</PMID>
  </results_reference>
  <results_reference>
    <citation>Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012 Apr;69(4):901-9. doi: 10.1007/s00280-011-1766-x. Epub 2011 Nov 12.</citation>
    <PMID>22080169</PMID>
  </results_reference>
  <results_reference>
    <citation>Gong K, Xie J, Yi H, Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012 May 1;443(3):735-46. doi: 10.1042/BJ20111685.</citation>
    <PMID>22339555</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, Nie LP, Wan J, Lu XP, Zhang W, Ning ZQ. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. Biomed Pharmacother. 2014 May;68(4):483-91. doi: 10.1016/j.biopha.2014.03.011. Epub 2014 Mar 18.</citation>
    <PMID>24721323</PMID>
  </results_reference>
  <results_reference>
    <citation>Frys S, Simons Z, Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol. 2015 May;169(4):506-19. doi: 10.1111/bjh.13318. Epub 2015 Feb 23.</citation>
    <PMID>25712263</PMID>
  </results_reference>
  <results_reference>
    <citation>Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia. 2010 Oct;24(10):1760-8. doi: 10.1038/leu.2010.157. Epub 2010 Aug 5.</citation>
    <PMID>20686505</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>May 1, 2016</last_update_submitted>
  <last_update_submitted_qc>May 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Yanyan Liu</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Relapsed and refractory</keyword>
  <keyword>Histone deacetylase inhibitor</keyword>
  <keyword>Chidamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

